Pfizer's Talzenna combination has reportedly achieved a significant win in treating castration-sensitive prostate cancer. The outcome may allow for earlier use of Talzenna, while competitors such as J&J are also making progress in the same area with their own treatments. The development is part of a broader effort by multiple companies, including Pfizer and Astellas, to build cases for their respective treatments in early-stage hormone-sensitive prostate cancer.